Khan Najat 4
4 · RECURSION PHARMACEUTICALS, INC. · Filed Feb 5, 2025
Insider Transaction Report
Form 4
Khan Najat
DirectorCEO and President
Transactions
- Award
Stock Option (Right to Buy)
2025-02-03+420,226→ 420,226 totalExercise: $7.25Exp: 2035-02-03→ Class A Common Stock (420,226 underlying) - Award
Class A Common Stock
2025-02-03+210,113→ 707,085 total - Award
Class A Common Stock
2025-02-03+8,049→ 715,134 total - Tax Payment
Class A Common Stock
2025-02-03$7.25/sh−2,753$19,959→ 712,381 total
Holdings
- 993,944
Stock Option (Right to Buy)
Exercise: $7.34Exp: 2034-08-01→ Class A Common Stock (0 underlying)
Footnotes (5)
- [F1]This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2025 and every three months thereafter.
- [F2]This RSU vested immediately upon the grant date.
- [F3]Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
- [F4]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F5]This option vests as to one fourth (1/4th) of the shares subject to the option on July 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.